Seizure prognosis in brain tumors: New insights and evidence-based management

Oncologist

Volumn 19, Issue 7, 2014, Pages 751-759

  Vecht, Charles J ^a,b   Kerkhof, Melissa ^b   Duran Pena, Alberto ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Department of Neurology Medical Center The Hague   (Netherlands)

Author keywords

Cancer; Epilepsy; Glioblastoma; Glioma; Guideline; Levetiracetam; Review; Seizures; Valproic acid

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; BEVACIZUMAB; BREAST CANCER RESISTANCE PROTEIN; ETIRACETAM; GABAPENTIN; HARKOSERIDE; HISTONE DEACETYLASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LAMOTRIGINE; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TEMOZOLOMIDE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VINCRISTINE; ZONISAMIDE; ANTICONVULSIVE AGENT;

ANTICONVULSANT THERAPY; ARTICLE; BRAIN TUMOR; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURGERY; DRUG POTENTIATION; EPENDYMOMA; EPILEPSY; EPILEPTOGENESIS; GENE MUTATION; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; NEUROTOXICITY; OLIGODENDROGLIOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEIZURE; TUMOR GROWTH; BRAIN NEOPLASMS; GLIOMA; PATHOPHYSIOLOGY; PROGNOSIS;

ANTICONVULSANTS; BRAIN NEOPLASMS; EPILEPSY; GLIOMA; HUMANS; PROGNOSIS;

EID: 84903625406     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0060     Document Type: Article

References (96)

1. Houillier C, Wang X, KaloshiGet al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560-1566.
2. Watanabe T, Nobusawa S, Kleihues P et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-1153.
3. Dubbink HJ, Taal W, van Marion R et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009;73:1792-1795.
4. Stockhammer F, Misch M, Helms HJ et al. IDH1/ 2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 2012;21:194-197.
5. Yuen TI, Morokoff AP, Bjorksten A et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology 2012;79:883-889.
6. Rosati A, Poliani PL, Todeschini A et al. Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol 2013;15: 618-625.
7. Huberfeld G, Wittner L, Clemenceau S et al. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci 2007;27:9866-9873.
8. Pallud J, Capelle L, Huberfeld G. Tumoral epileptogenicity: How does it happen? Epilepsia 2013;54(suppl 9):30-34.
9. Kahlenberg CA, Fadul CE, Roberts DW et al. Seizure prognosis of patients with low-grade tumors. Seizure 2012;21:540-545.
10. Rudà R, Bello L, Duffau H et al. Seizures in lowgrade gliomas: Natural history, pathogenesis, and outcome after treatments. Neuro Oncol 2012;14 (suppl 4):iv55-iv64.
11. Kerkhof M, Dielemans JC, van Breemen MS et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 2013;15:961-967.
12. Wick W, Menn O, Meisner C et al. Pharmacotherapy of epileptic seizures in glioma patients: Who, when, why and how long? Onkologie 2005;28: 391-396.
13. van Breemen MS, Rijsman RM, Taphoorn MJ et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 2009;256: 1519-1526.
14. Chang EF, Potts MB, Keles GE et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008;108:227-235.
15. Chaichana KL, Parker SL, OliviAet al. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 2009;111:282-292.
16. Hildebrand J, Lecaille C, Perennes J et al. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005; 65:212-215.
17. You G, Sha ZY, Yan W et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: A clinicopathological study. Neuro Oncol 2012;14: 230-241.
18. Rudà R, Magliola U, Bertero L et al. Seizure control following radiotherapy in patients with diffuse gliomas: A retrospective study. Neuro Oncol 2013;15:1739-1749.
19. Pignatti F, van den Bent M, Curran D et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20: 2076-2084.
20. Englot DJ, Han SJ, Berger MS et al. Extent of surgical resection predicts seizure freedom in lowgrade temporal lobe brain tumors. Neurosurgery 2012;70:921-928; discussion 928.
21. Duffau H, Capelle L, Lopes M et al. Medically intractable epilepsy from insular low-grade gliomas: Improvement after an extended lesionectomy. Acta Neurochir (Wien) 2002;144:563-572; discussion 572-573.
22. Pallud J, Audureau E, BlonskiMet al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137:449-462.
23. Martino J, Taillandier L, Moritz-Gasser S et al. Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas. Acta Neurochir (Wien) 2009;151: 427-436; discussion 436.
24. Luyken C, Blümcke I, Fimmers R et al. The spectrum of long-term epilepsy-associated tumors: Long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003;44:822-830.
25. Thom M, Blümcke I, Aronica E. Long-term epilepsy-associated tumors. Brain Pathol 2012;22: 350-379.
26. Englot DJ, BergerMS, BarbaroNMet al. Factors associated with seizure freedom in the surgical resection ofglioneuronal tumors. Epilepsia 2012;53: 51-57.
27. Southwell DG, Garcia PA, Berger MS et al. Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 2012;70:1406-1413; discussion 1413-1414.
28. Morioka T, Hashiguchi K, Nagata S et al. Additional hippocampectomy in the surgical management of intractable temporal lobe epilepsy associated with glioneuronal tumor. Neurol Res 2007;29:807-815.
29. Hu WH, Ge M, Zhang K et al. Seizure outcome with surgical management of epileptogenic ganglioglioma: A study of 55 patients. Acta Neurochir (Wien) 2012;154:855-861.
30. van den Bent MJ, Afra D, de WitteOet al. Longterm efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 2005;366:985-990.
31. Pace A, Vidiri A, Galiè E et al. Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol 2003;14:1722-1726.
32. Brada M, Viviers L, Abson C et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003;14: 1715-1721.
33. Kaloshi G, Benouaich-Amiel A, Diakite F et al. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68:1831-1836.
34. Sherman JH, Moldovan K, YeohHKet al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011;114:1617-1621.
35. Taillandier L, Duffau H. Epilepsy and insular grade II gliomas: An interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus 2009;27:E8.
36. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003;2:404-409.
37. Bénit C, Vecht CJ. Spectrum of side effects of anticonvulsants in patients with brain tumours. EANO Magazine 2012;2:15-24.
38. Glauser T, Ben-MenachemE, Bourgeois B et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54:551-563.
39. Glantz MJ, Cole BF, Forsyth PA et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000;54:1886-1893.
40. Soffietti R, Baumert BG, Bello Let al. Guidelines on management of low-grade gliomas: Report of an EFNS-EANO Task Force. Eur J Neurol 2010;17: 1124-1133.
41. Maschio M, Dinapoli L, Saveriano F et al. Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: Preliminary report. Acta Neurol Scand 2009;120:210-212.
42. Wagner GL, Wilms EB, Van Donselaar CA et al. Levetiracetam: Preliminary experience in patients with primary brain tumours. Seizure 2003;12: 585-586.
43. Maschio M, Albani F, Baruzzi A et al. Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 2006;80:97-100.
44. Maschio M, Dinapoli L, Sperati F et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: Seizure control, safety, and quality of life. J Neurooncol 2011;104:205-214.
45. Lim DA, Tarapore P, Chang E et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy:Arandomizedphase II pilot study. J Neurooncol 2009;93:349-354.
46. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 2006;78:99-102.
47. Rosati A, Buttolo L, Stefini R et al. Efficacy and safety of levetiracetam in patients with glioma: A clinical prospective study. Arch Neurol 2010;67: 343-346.
48. Bähr O, HermissonM, Rona S et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: The HELLO trial. Acta Neurochir (Wien) 2012;154:229-235; discussion 235.
49. de Groot M, Douw L, Sizoo EM et al. Levetiracetam improves verbal memory in high-grade glioma patients. Neuro Oncol 2013;15:216-223.
50. Bodalia PN, Grosso AM, Sofat R et al. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: Systematic review and network meta-analysis reveals the need for long term comparator trials. Br J Clin Pharmacol 2013; 76:649-667.
51. Newton HB, Dalton J, Goldlust S et al. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 2007;84:293-296.
52. Maschio M, Dinapoli L, Gomellini S et al. Antiepileptics in brain metastases: Safety, efficacy and impact on life expectancy. J Neurooncol 2010; 98:109-116.
53. Weller M, Gorlia T, Cairncross JG et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011;77:1156-1164.
54. Simó M, Velasco R, Graus F et al. Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. J Neurooncol 2012;108:451-458.
55. Otoul C, Arrigo C, van RijckevorselKet al. Metaanalysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28: 72-78.
56. Maschio M, Dinapoli L, Zarabla A et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 2008;86:61-70.
57. Lu Y, Yu W, Wang X. Efficacy of topiramate in adult patients with symptomatic epilepsy: An openlabel, long-term, retrospective observation. CNS Drugs 2009;23:351-359.
58. Mauro AM, Bomprezzi C, Morresi S et al. Prevention of early postoperative seizures in patients with primary brain tumors: Preliminary experience with oxcarbazepine. J Neurooncol 2007; 81:279-285.
59. Maschio M, Dinapoli L, Vidiri A et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: A comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 2009;28:60.
60. Maschio M, Dinapoli L, Sperati F et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: Open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neurooncol 2012;106:651-656.
61. Maschio M, Dinapoli L, Mingoia M et al. Lacosamide as add-on in brain tumor-related epilepsy: Preliminary report on efficacy and tolerability. J Neurol 2011;258:2100-2104.
62. Saria MG, Corle C, Hu J et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: Clinical article. J Neurosurg 2013;118:1183-1187.
63. Rossetti AO, Jeckelmann S, Novy J et al. Levetiracetam and pregabalin for antiepileptic monotherapyin patients with primary brain tumors. A phase II randomized study. Neuro Oncol 2014;16: 584-588.
64. French JA, Faught E. Rational polytherapy. Epilepsia 2009;50(suppl 8):63-68.
65. Brodie MJ, Sills GJ. Combining antiepileptic drugs-Rational polytherapy? Seizure 2011;20: 369-375.
66. Smits A, Duffau H. Seizures and the natural history of World Health Organization Grade II gliomas: A review. Neurosurgery 2011;68:1326-1333.
67. Aronica E, Gorter JA, Jansen GH et al. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003;118: 417-429.
68. Calatozzolo C, Pollo B, BotturiAet al. Multidrug resistance proteins expression in glioma patients with epilepsy. J Neurooncol 2012;110:129-135.
69. Loscher W. Mechanisms of drug resistance. Epileptic Disord 2005;7:S3-S9.
70. Zhang C, Zuo Z, Kwan P et al. In vitro transport profileofcarbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 2011;52:1894-1904.
71. Brodie MJ, Yuen AW. Lamotrigine substitution study: Evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26: 423-432.
72. Poolos NP, Warner LN, Humphreys SZ et al. Comparative efficacy of combination drug therapy in refractory epilepsy. Neurology 2012;78:62-68.
73. Kinirons P, McCarthy M, Doherty CP et al. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure 2006; 15:387-392.
74. Surges R, Volynski KE, Walker MC. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther AdvNeurol Disord 2008;1: 13-24.
75. Dudra-Jastrzebska M, Andres-Mach MM, Ratnaraj N et al. Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model. Seizure 2009;18:607-614.
76. Wojda E, Wlaz A, Patsalos PN et al. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Epilepsy Res 2009;86:163-174.
77. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004;3:159-168.
78. Oberndorfer S, Piribauer M, Marosi C et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72: 255-260.
79. Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg 2013;118: 859-865.
80. Barker CA, Bishop AJ, Chang M et al. Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 2013;86:504-509.
81. Felix FH, de Araujo OL, da Trindade KM et al. Survival of children with malignant brain tumors receiving valproate: A retrospective study. Childs Nerv Syst 2013;29:195-197.
82. Das CM, Aguilera D, Vasquez H et al. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007;85:159-170.
83. Roy Choudhury S, Karmakar S, Banik NL et al. Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98Gcells. Neurochem Res 2011;36:2292-2305.
84. Fujiwara Y, Yamamoto N, Yamada Y et al. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci 2009;100:1728-1734.
85. Kavanaugh SM, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010;67: 793-797.
86. Scherpereel A, Berghmans T, Lafitte JJ et al. Valproate-doxorubicin: Promising therapy for progressingmesothelioma. Aphase II study. Eur Respir J 2011;37:129-135.
87. Corsetti MT, Salvi F, Perticone S et al. Hematologic improvement and response in elderly AML/ RAEB patients treated with valproic acid and lowdose Ara-C. Leuk Res 2011;35:991-997.
88. Coronel J, Cetina L, Pacheco I et al. A doubleblind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 2011;28: S540-S546.
89. Chinnaiyan P, Cerna D, Burgan WE et al. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 2008;14: 5410-5415.
90. Bangert A, Cristofanon S, Eckhardt I et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-mycmediated downregulation of cFLIP. Oncogene 2012; 31:4677-4688.
91. Khalil MA, Hrabeta J, Cipro S et al. Neuroblastoma stem cells-Mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma 2012;59:737-746.
92. Bobustuc GC, Baker CH, Limaye A et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 2010;12:917-927.
93. Jaeckle KA, Ballman K, FurthAet al. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. Neurology 2009;73:1207-1213.
94. Birbeck GL, French JA, Perucca E et al. Antiepileptic drug selection for people with HIV/ AIDS: Evidence-based guidelines from the ILAE and AAN. Epilepsia 2012;53:207-214.
95. Chung S, Sperling MR, Biton V et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 2010; 51:958-967.
96. Baulac M, Brodie MJ, Patten A et al. Efficacy and tolerability of zonisamide versus controlledrelease carbamazepine for newly diagnosed partial epilepsy:Aphase 3, randomised, double-blind, noninferiority trial. Lancet Neurol 2012;11:579-588.